Texas ephedrine proposal
This article was originally published in The Tan Sheet
Executive Summary
State Board of Health approves on Jan. 14 issuing proposed regulations requiring that the FDA MedWatch toll-free number and a warning prohibiting sales to persons 17 or younger appear on the labeling of all ephedrine-containing dietary supplements. If made final, the MedWatch requirement will go into effect Sept. 1, 2001, giving FDA time to make planned changes to the MedWatch adverse event reporting system; the warning banning sale to minors would become effective Jan. 1, 2001. The proposed rule will be published in the Feb. 4 Texas Register for a 60-day comment period. The amendment to Texas' existing rules for ephedrine products was proposed last fall (1"The Tan Sheet" Nov. 15, 1999, p. 3). CFSAN Director Joseph Levitt, speaking at a CHPA regulatory forum on dietary supplements in Washington, D.C. Jan. 13, noted, "We advertise the MedWatch number every way we can. And if the state of Texas thinks that that's a good idea in this case...I'm not terribly bothered by that"
You may also be interested in...
Ephedrine Labeling MedWatch Reference Proposed In Texas
Texas is considering amending its rules pertaining to ephedrine-containing dietary supplements sold in the state to require the toll-free number for FDA's MedWatch adverse event reporting program on product labels. This would be the first time the MedWatch number has been required on a product.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands